Incretin Atlas › Trials › Retatrutide phase 2 (T2D)
Retatrutide phase 2 (T2D)
Retatrutide · t2d
Design
- Molecule(s)
- Retatrutide
- Population
- t2d
- Phase
- 2
- Participants
- 281
- Duration
- 36 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| retatrutide 12 mg | t2d | 36 | 281 | −16.9 % vs −3.0 % Δ −13.9 pp | — | −2.0 vs +0.0 | — | — | — | — | — | — | seed |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- retatrutide 12 mg: Values to be re-checked: the HbA1c shown is the 24-week value; the available text is an OCR scan (clean PDF requested).
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Retatrutide phase 2 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/retatrutide-phase-2-t2d/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.